CN117295511A - β淀粉样蛋白聚集抑制剂、β淀粉样蛋白聚集疾病用药物组合物及其用途 - Google Patents

β淀粉样蛋白聚集抑制剂、β淀粉样蛋白聚集疾病用药物组合物及其用途 Download PDF

Info

Publication number
CN117295511A
CN117295511A CN202280034441.6A CN202280034441A CN117295511A CN 117295511 A CN117295511 A CN 117295511A CN 202280034441 A CN202280034441 A CN 202280034441A CN 117295511 A CN117295511 A CN 117295511A
Authority
CN
China
Prior art keywords
peptide
amino acid
aggregation
amyloid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280034441.6A
Other languages
English (en)
Chinese (zh)
Inventor
秋泽俊史
齐藤源显
中村里菜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aureo Co ltd
Original Assignee
Aureo Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aureo Co ltd filed Critical Aureo Co ltd
Publication of CN117295511A publication Critical patent/CN117295511A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280034441.6A 2021-05-11 2022-05-10 β淀粉样蛋白聚集抑制剂、β淀粉样蛋白聚集疾病用药物组合物及其用途 Pending CN117295511A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-080513 2021-05-11
JP2021080513 2021-05-11
PCT/JP2022/019786 WO2022239765A1 (ja) 2021-05-11 2022-05-10 アミロイドβの凝集抑制剤、アミロイドβ凝集疾患用医薬組成物、およびその用途

Publications (1)

Publication Number Publication Date
CN117295511A true CN117295511A (zh) 2023-12-26

Family

ID=84029643

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280034441.6A Pending CN117295511A (zh) 2021-05-11 2022-05-10 β淀粉样蛋白聚集抑制剂、β淀粉样蛋白聚集疾病用药物组合物及其用途

Country Status (5)

Country Link
US (1) US20240238365A1 (https=)
EP (1) EP4338748A4 (https=)
JP (1) JPWO2022239765A1 (https=)
CN (1) CN117295511A (https=)
WO (1) WO2022239765A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022239764A1 (https=) * 2021-05-11 2022-11-17

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021345A1 (en) * 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2017119511A1 (ja) * 2016-01-06 2017-07-13 学校法人沖縄科学技術大学院大学学園 加水分解活性を示す新規ペプチドおよびその用途
AU2017254477A1 (en) * 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
EP3773625A4 (en) * 2018-03-29 2021-05-19 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR TREATMENT OF CANCER
JP7360155B2 (ja) 2019-11-18 2023-10-12 奥野製薬工業株式会社 無電解ニッケルめっき皮膜及び該無電解ニッケルめっき皮膜形成のための前処理方法

Also Published As

Publication number Publication date
EP4338748A4 (en) 2025-06-11
US20240238365A1 (en) 2024-07-18
WO2022239765A1 (ja) 2022-11-17
EP4338748A1 (en) 2024-03-20
JPWO2022239765A1 (https=) 2022-11-17

Similar Documents

Publication Publication Date Title
AU2018260893B2 (en) Neurodegenerative disorders
JP5801197B2 (ja) 痛みの治療に関する薬剤及び方法
AU2014228460B2 (en) Pharmaceutical compositions
KR101491860B1 (ko) Ｍｕ-코노톡신 펩티드 및 국소 마취제로서 그의 용도
WO2017147379A1 (en) Pharmacological modulators of nav1.1 voltage-gated sodium channels associated with mechanical pain
CN117295511A (zh) β淀粉样蛋白聚集抑制剂、β淀粉样蛋白聚集疾病用药物组合物及其用途
US9592279B2 (en) Agent for neuropathic pain
WO2022067086A1 (en) Methods of treating melanocortin-4 receptor pathway-associated disorders
TW202423471A (zh) 使用mc4r促效劑治療肥胖之方法
US11628206B2 (en) Method for inhibiting STAT3 activity comprising administering Ssu72
JP7629182B2 (ja) アミロイドβの凝集抑制剤、アミロイドβ凝集疾患用医薬組成物、およびその用途
EP4338747A1 (en) Alpha-synuclein aggregation inhibitor, pharmaceutical composition for alpha-synuclein disease, and use thereof
US20240173376A1 (en) Trem-1 inhibitors for the treatment of marfan syndrome
JP4760378B2 (ja) ＧＰＲ１０３−ｌｉｋｅ受容体蛋白質に対するリガンドの新規用途
EP1967210A1 (en) Novel application of apelin
US12441765B2 (en) Peptides and medical uses thereof
JP4760377B2 (ja) ＧＰＲ１０３−ｌｉｋｅ受容体蛋白質に対するリガンドの新規用途
WO2025106527A1 (en) Compositions and methods for the treatment of friedreich's ataxia
JP2019525931A (ja) ヒト成長ホルモンアナログによる成人成長ホルモン欠乏症の処置
US20220054583A1 (en) Peptides and medical uses thereof
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
RU2785889C1 (ru) Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4
JP2022112968A (ja) アミロイドβの凝集抑制剤、アミロイドβ凝集疾患用医薬組成物、およびその用途
US20210169980A1 (en) Autophagy inhibitors
Ehrlich Aus dem Institut für Experimentelle und Klinische Pharmakologie und Toxikologie der Universität zu Lübeck Direktor: Prof. Dr. Markus Schwaninger und aus den Departments of Pharmacology and Cellular and Molecular Physiology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination